Major pharma company will announce licensing, acquisition or partnership with psychedelic biotech before January 2027.

One of the world's largest pharmaceutical companies — Pfizer, J&J, Eli Lilly, Roche, or similar — will likely announce a deal with a psychedelic drug company before the year is out, following the same playbook used with gene therapy and GLP-1 drugs.

Big Pharma enters emerging categories after Phase 3 proof-of-concept and regulatory clarity. Both now exist. Approval race creates urgency. Psychedelic stigma and IP complexity may delay into 2027. 62% reflects strong logic with execution timing uncertainty.